Literature DB >> 11421916

The role of CD30 in atopic disease.

A Bengtsson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11421916     DOI： 10.1034/j.1398-9995.2001.00137.x

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  9 in total

Review 1.  Brentuximab vedotin.

Authors:  Niels W C J van de Donk; Eugen Dhimolea
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 2.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

3.  Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease.

Authors:  C Baker; L Chang; K A Elsegood; A J Bishop; D H Gannon; P Narendran; N J Leech; C M Dayan
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

Review 4.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

5.  Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.

Authors:  Shehnaz K Hussain; Nancy A Hessol; Alexandra M Levine; Elizabeth Crabb Breen; Kathryn Anastos; Mardge Cohen; Gypsyamber D'Souza; Deborah R Gustafson; Sylvia Silver; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

6.  Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications.

Authors:  Nima Rezaei; Mostafa Haji-Molla-Hoseini; Asghar Aghamohammadi; Ali Akbar Pourfathollah; Mina Moghtadaie; Zahra Pourpak
Journal:  J Clin Immunol       Date:  2007-10-03       Impact factor: 8.317

7.  CD30 is required for activation of a unique subset of interleukin-17A-producing γδ T cells in innate immunity against Mycobacterium bovis Bacillus Calmette-Guerin infection.

Authors:  Ying Guo; Xun Sun; Kensuke Shibata; Hisakata Yamada; Hiromi Muta; Eckhard R Podack; Yasunobu Yoshikai
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

8.  Characterization of CD30/CD30L(+) Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis.

Authors:  Alessandro Barbieri; Marzia Dolcino; Elisa Tinazzi; Antonella Rigo; Giuseppe Argentino; Giuseppe Patuzzo; Andrea Ottria; Ruggero Beri; Antonio Puccetti; Claudio Lunardi
Journal:  J Immunol Res       Date:  2015-05-19       Impact factor: 4.818

9.  Study of the expression of CD30 in pterygia compared to healthy conjunctivas.

Authors:  Yonathan Garfias; Víctor Manuel Bautista-De Lucio; Cynthia García; Angel Nava; Leonardo Villalvazo; María Carmen Jiménez-Martínez
Journal:  Mol Vis       Date:  2009-10-17       Impact factor: 2.367
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.